BWXT Medical Executes Commercial Agreement with Bayer for Supply of Actinium-225 Based Products
(OTTAWA, ON – June 27, 2022) – BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT Medical Ltd. has executed a commercial agreement with Bayer AG (Bayer) to supply high-purity Actinium-225 (Ac-225).
BWXT Medical and TRIUMF Execute Agreement for Manufacture of High Purity Ac-225 Based Products
BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT Medical Ltd. and TRIUMF, Canada’s particle accelerator centre, have executed a licensing and services agreement that strengthens their existing partnership for the production of medical isotopes.
BWXT to Build First Advanced Microreactor in United States
(LYNCHBURG, Va. – June 9, 2022) – BWX Technologies, Inc. (NYSE: BWXT) will build the first advanced nuclear microreactor in the United States under a contract awarded by the U.S. Department of Defense (DoD) Strategic Capabilities Office (SCO). The Project Pele full-scale transportable microreactor prototype will be completed and delivered in 2024 for testing at the Idaho National Laboratory.